Fanconi Syndrome Induced by Vemurafenib: A New Renal Adverse Event

Vemurafenib is a BRAF inhibitor approved by the US Food and Drug Administration as treatment for patients with unresectable or metastatic melanoma harboring the BRAF... »

Source: JAMA Oncology - December 11, 2014 Category: Cancer & Oncology Authors: Daphné Denis, MD and colleagues Tags: Clinical Review & Education JAMA Dermatology Observation Source Type: research